46 completed, 16 recruiting, 12 unknown, 10 not yet recruiting. 108 Phase 2, 36 Phase 1, 13 Phase 3.
Follow Hearing Loss: new trials by email Literature Review of Hearing Loss trials Research Report on Hearing Loss
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First In Human Randomised Trial of Rincell-1 in Adults With a Cochlear Implant Otic neural progenitors, cochlear implantation - Sensorineural Hearing Loss, Presbyacusis | Phase 1 / Phase 2 | Not yet recruiting | Rinri Therapeutics | 20 | 2027-09-01 | 2026-10-01 |
| A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus) Glycerol Tributyrate - MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus) | Phase 1 / Phase 2 | Not yet recruiting | George Washington University | 24 | 2027-03-01 | 2026-10-05 |
| A Study Testing the Safety and Possible Benefits of an Ear Injection of a New Compound, Paliroden, in People With Type 2 Diabetes Who Have Difficulty Understanding Speech in Noisy Situations CIL001 (Paliroden), Placebo - Cochlear Synaptopathy | Phase 1 / Phase 2 | Not yet recruiting | Cilcare SAS | 135 | 2027-01-01 | 2026-10-26 |
| A Study Testing Safety and Efficacy of Transtympanic Paliroden for the Treatment of Cochlear Synaptopathy in Participants With Chronic, Constant Tinnitus paliroden (CIL001), Placebo - Tinnitus, Bilateral, Cochlear Synaptopathy | Phase 1 / Phase 2 | Not yet recruiting | Cilcare SAS | 60 | 2027-01-01 | 2026-09-17 |
| Verification of the Efficacy/Safety of the Mixed Drug Injectable Delivery Vehicle for Treating Intractable Hearing Loss Dexamethasone, Hyaluronic acid, Indocyanine green(ICG) - Hearing Loss, Sensorineural, Hearing Loss, Sudden | Phase 1 / Phase 2 | Withdrawn | Seoul National University Hospital | 2026-12-15 | 2026-05-22 | |
| SPI-1005 in Adults Receiving Cochlear Implant Ebselen, Placebo - Hearing Loss, Cochlear Trauma | Phase 2 | Recruiting | Sound Pharmaceuticals, Incorporated | 40 | 2026-12-01 | 2026-06-26 |
| Study to Evaluate the Long-Term Safety of Ultevursen in Participants With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene No intervention, will not receive any active study intervention, Intravitreal Injection of Ultevursen - Retinitis Pigmentosa (RP), Usher Syndrome Type 2 | Phase 2 | Not yet recruiting | Laboratoires Thea | 81 | 2026-10-05 | 2026-09-01 |
| Efficacy and Safety of Intracochlear Injection of Glucocorticoid Through the Round Window Membrane in Patients With Profound or Complete Sudden Sensorineural Hearing Loss intracochlear injection of triamcinolone acetonide through the round window membrane, intratympanic dexamethasone injection through the tympanic membrane - Sudden Hearing Loss | Phase 2 | Not yet recruiting | Eye & ENT Hospital of Fudan University | 56 | 2026-09-15 | 2026-09-11 |
| SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss SPI-1005 Low Dose, SPI-1005 Middle Dose, SPI-1005 High Dose - Lung Cancer, Head and Neck Cancer | Phase 2 | Withdrawn | Sound Pharmaceuticals, Incorporated | 2026-06-01 | 2026-06-03 | |
| A Phase 2b Study of SPI-1005 to Prevent Acute Noise Induced Hearing Loss SPI-1005 200mg, SPI-1005 400mg, Placebo - Noise Induced Hearing Loss | Phase 2 | Withdrawn | Sound Pharmaceuticals, Incorporated | 2026-06-01 | 2026-06-03 | |
| Open-label Study of SKY-GJB2 in Pediatric Subjects With GJB2-mediated Hearing Loss SKY-GJB2 - GJB2-mediated Hearing Loss, GJB2 Gene Mutation | Phase 1 / Phase 2 | Recruiting | Skylark Bio Inc. | 10 | 2026-05-28 | 2026-08-27 |
| Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS) Pedmark® STS - Solid Tumor Malignancies, Testicular Cancer | Phase 1 / Phase 2 | Recruiting | University of Arizona | 25 | 2026-05-18 | 2026-06-18 |
| First Clinical Study to Evaluate Safety, Tolerability & PK of DX243 in Healthy Volunteers and Patients With Hearing Loss DX243, Placebo - Age-related Hearing Loss | Phase 2 | Recruiting | Dendrogenix | 24 | 2026-05-13 | 2026-06-10 |
| Trans-round Window Membrane Intracochlear Steroid Experimental: Group A: intracochlear triamcinolone acetonide injection, intracochlear injection of dexamethasone, intratympanic dexamethasone injection - Sudden Hearing Loss | Phase 2 | Not yet recruiting | Eye & ENT Hospital of Fudan University | 108 | 2026-04-20 | 2026-04-20 |
| Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss Tympanic injection of hUC-MSC-sEV-003 (small extracellular vesicles) at low doses, Tympanic injection of hUC-MSC-sEV-003 (small extracellular vesicles) at moderate doses, Tympanic injection of hUC-MSC-sEV-003 (small extracellular vesicles) at high doses - Sudden Hearing Loss, Extracellular Vesicles | Phase 1 / Phase 2 | Not yet recruiting | The Affiliated Hospital of Qingdao University | 9 | 2026-02-28 | 2026-03-25 |
| Intracochlear Injection of Glucocorticoid intracochlear triamcinolone acetonide injection, intracochlear injection of dexamethasone through the round window membrane, intracochlear dexamethasone injection and intratympanic dexamethasone injection - Sudden Sensorineural Hearing Loss (SSNHL) | Phase 2 | Not yet recruiting | Eye & ENT Hospital of Fudan University | 150 | 2025-08-25 | 2025-08-21 |
| Long-Term Outcomes of Early Communication Intervention for Deaf/Hard of Hearing Toddlers Parent-Mediated Intervention (PMI) - Hearing Loss, Bilateral | Phase 2 | Enrolling by invitation | Northwestern University | 88 | 2025-08-12 | 2026-06-01 |
| A Prospective, Open-label, Pivotal Study to Assess Spectacle Hearing Aid Safety and Efficacy Spectacle Hearing Aid - Hearing Loss Mixed | Phase 2 / Phase 3 | Recruiting | Nuance Hearing | 89 | 2025-07-27 | 2025-12-15 |
| Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin ORC-13661, Placebo - Ototoxicity, Drug-Induced | Phase 2 | Recruiting | Kevin Winthrop | 105 | 2025-06-02 | 2026-10-01 |
| A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound Clemastine Fumarate Combined With Engineered Sound, Clemastine Fumarate Combined With Pink Noise, Placebo Drug With Engineered Sound - Central Auditory Processing Disorder, Hearing Impaired (Partially) | Phase 1 / Phase 2 | Recruiting | University of Colorado, Denver | 344 | 2025-03-31 | 2026-04-30 |
Showing 20 of 108. Sign in to see all of them.
Hearing Loss, Sensorineural (25) · Hearing Loss, Sudden (19) · Deafness (12) · Hearing Loss, Noise-Induced (12) · Tinnitus (12) · Usher Syndromes (12) · Retinitis Pigmentosa (10) · Ototoxicity (7) · Vision Disorders (7) · Hearing Disorders (6) · Hearing Loss, Bilateral (6) · Hearing Loss, Hidden (6) · Meniere Disease (6) · Retinal Diseases (6)
Nervous System Diseases (108) · Sensation Disorders (108) · Neurologic Manifestations (107) · Otorhinolaryngologic Diseases (106) · Pathological Conditions, Signs and Symptoms (104) · Signs and Symptoms (104) · Ear Diseases (103) · Hearing Disorders (102) · Hearing Loss, Sensorineural (24) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (22) · Genetic Diseases, Inborn (20) · Abnormalities, Multiple (18) · Congenital Abnormalities (18) · Blindness (17)
ebselen (7) · Acetylcysteine (5) · Dexamethasone (4) · Intravitreal Injections (4) · Hyaluronic Acid (3) · Zonisamide (3) · AUT00063 (2) · Capsules (2) · Cochlear Implantation (2) · Hearing Aids (2) · Interleukin 1 Receptor Antagonist Protein (2) · SENS-401 (2) · Saline Solution (2) · Valganciclovir (2) · Valproic Acid (2)
Sound Pharmaceuticals, Incorporated (7) · Laboratoires Thea (5) · US Department of Veterans Affairs (5) · Washington University School of Medicine (4) · Eye & ENT Hospital of Fudan University (3) · Frequency Therapeutics (3) · Sensorion (3) · University of Colorado, Denver (3) · Andrea Vambutas (2) · Autifony Therapeutics Limited (2) · Chang Gung Memorial Hospital (2) · Cilcare SAS (2) · National Taiwan University Hospital (2) · Northwestern University (2) · Otonomy, Inc. (2)
United States (56) · France (12) · United Kingdom (11) · Germany (9) · Canada (7) · China (5) · Israel (4) · Italy (4) · Taiwan (4) · Australia (3) · Brazil (3) · Czechia (3) · Netherlands (3) · Spain (3) · Belgium (2)
Jonathan Kil, MD (6) · Carl LeBel, PhD (3) · Yilai Shu, MD, Ph.D (3) · Andrea Vambutas, MD (2) · Craig A Buchman, MD, FACS (2) · Huawei Li, MD, Ph.D (2) · Aaron Tward, MD (1) · Achim Klug, PhD (1) · Albert Park, MD (1) · Alejandro Recio-Boiles, MD (1) · Anne Chiaramello, Ph.D. (1) · Benoit Mongourdin, PH (1)
PMID 24975234, PMID 25133431, PMID 10459293, PMID 11074842, PMID 11283492, PMID 11587599, PMID 12697801, PMID 12697802, PMID 16244757, PMID 16244758, PMID 16244759, PMID 17030153, PMID 17450108, PMID 20398111, PMID 20638463, PMID 21974483, PMID 22122960, PMID 24705452, PMID 25017670, PMID 25073872, PMID 25690605, PMID 28716314, PMID 29457537, PMID 31215818, PMID 32483557, PMID 34185708, PMID 34301203, PMID 34510123, PMID 37418643, PMID 38309519, PMID 38415855, PMID 40010822, PMID 40339601, PMID 41085057, PMID 42479273
2023 (2), R33DC011827 (2), 2015 (1), 2018 (1), 2025 (1), R21DK113487 (1), U01DC008423 (1), U01DC014706 (1), U01DC020175 (1), UH3TR003897 (1)